Research topics & objectives
The team’s objectives are to: describe and understand the oncogenic alterations implicated in the transformation of normal lymphocytes into lymphoma cells in order to improve the diagnostic and therapeutic care of patients suffering from lymphomas; understand the mechanisms responsible for the decrease in anti-cancer T-cell responses linked to the expression of the immunosuppressive enzyme IL4I1.Research topics
- Oncogenesis of T-cell lymphomas
- Identification of diagnostic biomarkers, lymphoma prognostics and theranostics
- Immunoregulation with the enzyme IL4I1
Lymphoma sub-types
- Peripheral T-cell lymphoma
- B-cell lymphomas (diffuse large B-cell lymphomas)
Key words
Peripheral T-cell lymphomas, Oncogenesis, IL4I1, Biomarkers

Philippe
Gaulard
Manager - Créteil

Expertise
Expertise
BIOLOGICAL TARGETS AND IN VITRO/IN VIVO/EX VIVO MODELS
Targets
- Alterations in the epigenetic regulators and in cell signalling (particularly in the TCR and co-stimulation molecule pathway) in T-cell lymphomas
- Immunomodulatory effect of the enzyme IL4I1
- Target study on tumour lymphoid lineages (B and T cells)
- TET2, c-MYC, IDO, IL4I1
Models
- Mouse KO IL4I1, double KO IL4I1/IDO
- Many lymphoid lineages (B and T cells)
- Transgenic mouse model P14 (TCR antigp33)
BLOOD AND TISSUE BIOMARKERS
- Identification of somatic mutations: targeted sequencing or not (Sanger, PCR all spé, NGS, HRM), allelic discrimination
- Genetic tissue expression profile: RT-PCR, micro-arrays, RT-MLPA
- Identification of quantitative or structural genetic alterations (FISH, a CGH)
- Protein analysis in situ: immunohistochemistry for the expression of tumour markers and markers of the immune microenvironment, of which IL4I1 (monoclonal antibody developed by the team)
- Tracking T or NK lymphoid populations (blood) and the residual disease (blood, marrow) (during treatment)
TOOLS, PROCESSES AND PLATFORMS LINKED TO THE CLINICAL RESEARCH
Biological resources/collections:
- TENOMIC collection of more than 900 T-cell lymphomas, annotated with molecular data
- Collections of cutaneous lymphomas (KIRs, CELLUCUT and LYCUT)
- Collections GHEDI, MALT…
- The Mondor biological resource platform
Imaging platform(immunohistochemistry, FISH, TMAs, virtual slides and image analysis linked to the LYSA-P platform).
Clinical resources:
- -LYSA trials
- CLIP2 (early phase clinical trial centre with the INCa label), for the development of early trials
INNOVATING TECHNOLOGY
- NGS (NGS panel of T-cell lymphomas)
- RT-MLPA
- a-CGH
- Circulating DNA: liquid biopsy
Platforms & technical resources
- Imaging platform (immunohistochemistry, FISH, TMAs, virtual slides and image analysis linked to the LYSA-P platform)
- Microscopy
- FISH
- Tissue micro-arrays
- Virtual images
- NGS genomic platform…
R&D offer
- In vitro pre-clinical models
- Access to annotated and well-characterised lymphoma collections (more than 800 T-cell lymphomas in the collection TECNOMIC)
- Histopathology, immunohistochemistry, FISH, molecular diagnostic, immunomonitoring
- Early clinical trials